LEXICON PHARMACEUTICALS INC (LXRX)
Health Care · Cardiovascular, metabolic, and neuropathic disease therapeutics · NASDAQ
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by commercialized INPEFA and Phase 3 hypertrophic cardiomyopathy candidate sotagliflozin.
What LEXICON PHARMACEUTICALS INC does
Lexicon Pharmaceuticals is a biopharmaceutical company developing small-molecule drug candidates and commercializing INPEFA (sotagliflozin) for cardiovascular and metabolic indications. The company is advancing sotagliflozin in hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin in neuropathic pain, and has licensed LX9851 to Novo Nordisk for obesity and cardiometabolic disorders, while pursuing preclinical programs based on target-driven drug discovery from systematic gene knockout studies.
Themes: cardiovascular disease, diabetes management, chronic kidney disease (CKD), neuropathic pain, obesity treatments, small molecule drugs, drug discovery platform
Fundamentals
- Price$2.30 as of 2026-08-21 close
- Market cap$1.0B as of 2026-08-21
- 1-year return+96.6% 2025-08-21 close $1.17 → 2026-08-21 close $2.30
- P/En/a negative earnings
- Net margin-37.5% as of 2026-08-24
- Gross margin+99.5% as of 2026-08-24
- ROE-18.6% as of 2026-08-24
- Debt / equity0.24 as of 2026-08-24
- Revenue growth (YoY)+123.1% as of 2026-08-24
- Revenue CAGR (3y)+610.3% SEC XBRL
- Beta1.06 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LXRX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LEXICON PHARMACEUTICALS INC looks technically
LEXICON PHARMACEUTICALS INC (LXRX) is trading 32.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 267 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move.
Trend
7
| Distance from the 200-day | it is trading 32.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +32.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.28 | $2.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.74 | $1.74 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 267 trading days ago — a "golden cross", a bullish long-term signal | 267 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 48.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.96 to $2.52) — its "stochastic" reading is 61 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 60.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.68 | $2.68 |
|---|---|---|
| From the 52-week high | it is 14.2% below its 52-week high (its highest price of the past year) | -14.2% |
| Above the 52-week low | it is 123.3% above its 52-week low (its lowest price of the past year) | +123.3% |
| Below the 52-week high | it is 14.2% below its highest point of the past year | 14.2% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $45.45 (set on 2005-07-18) | $45.45 |
| Given back of the 52-week move | over the past year its closes ranged ($1.07 to $2.64), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.62 to $1.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.7% |
| From the all-time high | it is 94.9% below its all-time high | -94.9% |
| Nearest price level | it is trading 5.8% above a support level at $2.17 — a price it turned at twice since 2024-10-18, most recently on 2026-07-27. Since 2024-08-21 it has 16 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.8% |
| All-time low | its lowest closing price on record is $0.2836 (set on 2025-03-03) | $0.2836 |
| Above the all-time low | it is 711.0% above its all-time low | +711.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1447 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1447 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.21 and $2.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.21 – $2.36 – $2.51 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (32.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.13× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.5% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.7 percentage points (the stock lost 3.4% while the market gained 2.3%) | -5.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock has tracked the market almost exactly (the stock gained 3.1% while the market gained 3.1%) | +0.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 45.4 percentage points (the stock gained 56.5% while the market gained 11.1%) | +45.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 76.1 percentage points (the stock gained 96.6% while the market gained 20.5%) | +76.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.5% of the share price. | +2.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.91 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +20.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.35 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -2.2% |
Price levels it has turned at before
LXRX last closed at $2.30 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.17 | Support | 5.8% below the last close | turned there twice · 2024-10-18 to 2026-07-27 |
| $2.52 | Resistance | 9.8% above the last close | turned there twice · 2026-05-12 to 2026-08-04 |
| $2.04 | Support | 11.4% below the last close | turned there twice · 2026-05-19 to 2026-07-15 |
| $1.96 | Support | 15.0% below the last close | turned there twice · 2026-04-17 to 2026-08-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · beating the market · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$3.86 range $2.00 – $6.00; median $3.10
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LXRX
- Consensus EPS estimate-$0.0529 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory risk: ZYNQUISTA NDA for type 1 diabetes has received two complete response letters and is under FDA Notice of Opportunity for Hearing proceedings; approval uncertain pending third-party safety study","Commercial traction risk: Net product revenue of $1.1M in Q1 2026 indicates early-stage INPEFA commercialization; profitability and market adoption uncertain","Partnership dependency: LX9851 obesity program entirely dependent on Novo Nordisk development and commercialization; pilavapadin advancement relies on third-party collaboration discussions"]
What changed in the latest 10-Q
AI-assisted comparison of LXRX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added language that FDA provided feedback that a third-party-funded, investigator-initiated study of sotagliflozin appears adequate to provide viable evidence on DKA incidence and safety prior to completion to support NDA resubmission review (filed 2026-05-07)
- Added statement that company is preparing to potentially resubmit NDA for ZYNQUISTA in type 1 diabetes if supported by patient exposure and safety data from such study (filed 2026-05-07)
- Added reference to 'PROGRESS Phase 2b clinical trial' and 'RELIEF-DPN-1 Phase 2a clinical trial' with specific naming (filed 2026-05-07)
- Added statement that company is 'currently advancing third party collaboration discussions' for pilavapadin development and commercialization (filed 2026-05-07)
- Added clarification that Novo Nordisk is 'currently conducting Phase 1 development' of LX9851 (filed 2026-05-07)
- Removed:
- Removed reference to pilavapadin alternative name '(LX 9211)' (filed 2025-11-06)
- Removed statement that company 'have completed three Phase 2 clinical trials' - changed to 'two Phase 2 clinical trials' (filed 2025-11-06)
- Removed reference to results from 'a separate Phase 2a clinical trial of pilavapadin in post-herpetic neuralgia' (filed 2025-11-06)
- Removed reference to company 'are conducting preclinical development of LX9851 in preparation for the filing of an investigational new drug application' (filed 2025-11-06)
- Removed statement that INPEFA is 'our orally-delivered small molecule drug' (filed 2025-11-06)
- Removed bullet point about sotagliflozin HCM development appearing as separate item in older version (filed 2025-11-06)
- Removed reference to 'an additional complete response letter in December 2024 regarding our NDA for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and CKD' (filed 2025-11-06)
- Reworded:
- Reorganized sotagliflozin HCM into first bullet point rather than separate paragraph (filed 2026-05-07)
- Changed 'three Phase 2 clinical trials' to 'two Phase 2 clinical trials' for pilavapadin (filed 2026-05-07)
- Reordered pilavapadin and LX9851 bullet points (pilavapadin moved before LX9851 in newer version) (filed 2026-05-07)
- Changed reference to complete response letters from 'an additional complete response letter in December 2024' to 'complete response letters regarding our New Drug Application' listing March 2019 and December 2024 separately (filed 2026-05-07)
- Reordered opening disclosure about sotagliflozin HCM to appear as first development program bullet (filed 2026-05-07)
- Reordered listing of drug program origins (filed 2026-05-07)
- Notes:
- Text truncated at 'Critical Accounting Policies' section in both versions, so comparison limited to Overview section
- Older filing section appears to have formatting issue with 'ev aluating' (spacing error in source text)
- Page numbering differs: older version shows '17' while newer shows '16', indicating possible layout changes
Risk Factors
- Added:
- Reference to annual report on Form 10-K for the year ended December 31, 2025 (newer filing, filed 2026-05-07)
- Balance sheet as of March 31, 2026 showing cash and cash equivalents of $38,089 thousand
- Balance sheet as of March 31, 2026 showing short-term investments of $132,569 thousand
- Convertible preferred stock line item with 408,435 shares outstanding at March 31, 2026
- Current portion of long-term debt of zero as of March 31, 2026
- Three months ended March 31, 2026 revenues including $20,000 thousand licensing and milestone revenue
- Three months ended March 31, 2026 net loss of $1,043 thousand
- Condensed Consolidated Statements of Stockholders' Equity section showing stock activity for the three months ended March 31, 2026
- Issuance of preferred stock of 408 shares for $26,548 thousand (net of fees) in first quarter 2026
- Issuance of common stock of 56,489 shares for $69,673 thousand (net of fees) in first quarter 2026
- Condensed Consolidated Statements of Cash Flows for three months ended March 31, 2026
- Removed:
- Reference to annual report on Form 10-K for the year ended December 31, 2024 (older filing, filed 2025-11-06)
- Balance sheet as of September 30, 2025 showing cash and cash equivalents of $49,656 thousand
- Balance sheet as of September 30, 2025 showing short-term investments of $66,294 thousand
- Preferred stock line item showing zero outstanding shares as of September 30, 2025
- Deferred revenue of $4,303 thousand in current liabilities as of September 30, 2025
- Nine months ended September 30, 2025 financial statements and comprehensive income statement
- Three months ended September 30, 2025 revenues including $13,154 thousand licensing revenue
- Nine months ended September 30, 2025 revenues of $44,310 thousand
- Condensed Consolidated Statements of Stockholders' Equity section showing activity through September 30, 2025
- Net income of $3,252 thousand for six months ended June 30, 2025
- Condensed Consolidated Statements of Cash Flows for nine months ended September 30, 2025
- Reworded:
- Comprehensive loss statement changed from 'Condensed Consolidated Statements of Comprehensive Income (Loss)' to 'Condensed Consolidated Statements of Comprehensive Loss'
- Unrealized loss on investments line item changed from 'Unrealized gain (loss) on investments' format in older to 'Unrealized loss on investments' in newer
- Cash flow statement period changed from nine months ended September 30 to three months ended March 31
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs Q3 2025), making direct year-over-year comparison limited
- Financial data is unaudited in both presentations
- The stockholders' equity statement shows different activity because the newer filing includes preferred stock issuances that were not present in the prior period comparison shown in the older filing
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LXRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LXRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 52,630,396
- Reported value $82,103,417
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LXRX had 32,825,365 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LXRX had 7.38% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.46 days to cover at the same settlement.
- Reported short interest (shares) 32,825,365
- Short interest (% of shares outstanding) 7.38%
- Prior settlement (shares) 32,730,919
- Reported change 0.29%
- Days to cover (reported) 12.46
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novo Nordisk (NVO) - obesity and diabetes
- AstraZeneca (AZN) - heart failure and cardiovascular
- Boehringer Ingelheim - SGLT inhibitors and heart failure
- Bayer (BAYN) - cardiovascular and kidney disease
- Eli Lilly (LLY) - diabetes and obesity
- Pfizer (PFE) - cardiovascular and diabetes
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LXRX vs…
LXRX ranks in…
Frequently asked questions
What does LEXICON PHARMACEUTICALS INC (LXRX) do?
Lexicon Pharmaceuticals is a biopharmaceutical company developing small-molecule drug candidates and commercializing INPEFA (sotagliflozin) for cardiovascular and metabolic indications. The company is advancing sotagliflozin in hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin in neuropathic pain, and has licensed LX9851 to Novo Nordisk for obesity and cardiometabolic disorders, while pursuing preclinical programs based on target-driven drug discovery from systematic gene knockout…
What sector is LEXICON PHARMACEUTICALS INC (LXRX) in?
LEXICON PHARMACEUTICALS INC (LXRX) is classified in the Health Care sector. Its industry is Cardiovascular, metabolic, and neuropathic disease therapeutics. It trades on NASDAQ.
Who are LEXICON PHARMACEUTICALS INC's (LXRX) competitors?
Notable peers of LEXICON PHARMACEUTICALS INC (LXRX) include Novo Nordisk (NVO) - obesity and diabetes, AstraZeneca (AZN) - heart failure and cardiovascular, Boehringer Ingelheim - SGLT inhibitors and heart failure, Bayer (BAYN) - cardiovascular and kidney disease and Eli Lilly (LLY) - diabetes and obesity. This peer set is informational only — not financial advice.
Is LEXICON PHARMACEUTICALS INC (LXRX) overbought or oversold right now?
LEXICON PHARMACEUTICALS INC (LXRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LXRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.